Cannabis sativa and Hemp

Nutraceuticals: Efficacy, Safety and Toxicity

Volumn , Issue , 2016, Pages 735-754

  Hartsel, Joshua A ^a   Eades, Joshua ^a   Hickory, Brian ^b   Makriyannis, Alexandros ^c  

^a Delta 9 Technologies   (United States)

^b Sustainable Syntheses   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Cannabidiol; Cannabis sativa; CBD; Hemp; Nutraceutical; Nutritional supplement; Tetrahydrocannabinol; THC

Indexed keywords

EID: 84966750097     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-802147-7.00053-X     Document Type: Chapter

References (139)

1. Aggarwal B.B., Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 2006, 71(10):1397-1421.
2. Ahmed S.A., Ross S.A., Slade D., et al. Cannabinoid ester constituents from high-potency Cannabis sativa. J. Nat. Prod. 2008, 71(4):536-542.
3. Aldrich M., Mathre M. History of Therapeutic Cannabis. Cannabis in Medical Practice 1997, McFarland, Jefferson, NC, pp. 35-55.
4. Al-Omari, S.M., 2007. The Effect of Thujone and Myrcene on Diabetes Mellitus in Albino Rats. (MS), University of Jordan.
5. Anderson L.C. Leaf variation among Cannabis species from a controlled garden. Bot. Mus. Leaf. Harv. Univ. 1980, 28(1):61-69. doi:10.2307/41762825.
6. Appendino G., Gibbons S., Giana A., et al. Antibacterial cannabinoids from Cannabis sativa: a structure - activity study. J. Nat. Prod. 2008, 71(8):1427-1430.
7. Appendino G., Chianese G., Taglialatela-Scafati O. Cannabinoids: occurrence and medicinal chemistry. Curr. Med. Chem 2011, 18(7):1085-1099.
8. Bahi A., Al Mansouri S., Al Memari E., et al. β-Caryophyllene, a CB 2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. Physiol. Behav. 2014, 135:119-124.
9. Barni-Comparini I., Ferri S., Centini F. Cannabinoid level in the leaves as a tool for the early discrimination of Cannabis chemiovariants. Forens. Sci. Intl. 1984, 24(1):37-42.
10. Barrett M.L., Scutt A.M., Evans F.J. Cannflavin A and B, prenylated flavones from Cannabis sativa L. Experientia 1986, 42(4):452-453.
11. Basha R.H., Sankaranarayanan C. β-Caryophyllene, a natural sesquiterpene, modulates carbohydrate metabolism in streptozotocin-induced diabetic rats. Acta Histochem. 2014, 116(8):1469-1479.
12. Bento A.F., Marcon R., Dutra R.C., et al. β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through CB2 receptor activation and PPARγ pathway. Am. J. Pathol. 2011, 178(3):1153-1166.
13. Bergamaschi M.M., Queiroz R.H.C., Chagas M.H.N., et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 2011, 36(6):1219-1226.
14. Bertoli A., Tozzi S., Pistelli L., et al. Fibre hemp inflorescences: from crop-residues to essential oil production. Ind. Crops Prod. 2010, 32(3):329-337.
15. Borrelli F., Fasolino I., Romano B., et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem. Pharmacol. 2013, 85(9):1306-1316.
16. Brenneisen R. Chemistry and analysis of phytocannabinoids and other Cannabis constituents. Marijuana and the Cannabinoids 2007, Springer, pp. 17-49.
17. Brenneisen R., ElSohly M.A. Chromatographic and spectroscopic profiles of Cannabis of different origins: part I. J. Forens. Sci. 1988, 33(6):1385-1404.
18. Broséus J., Anglada F., Esseiva P. The differentiation of fibre- and drug type Cannabis seedlings by gas chromatography/mass spectrometry and chemometric tools. Forens. Sci. Intl. 2010, 200(1-3):87-92.
19. Callaway J.C. Hempseed as a nutritional resource: an overview. Euphytica 2004, 140(1-2):65-72.
20. Calleja M.A., Vieites J.M., Montero-Meterdez T., et al. The antioxidant effect of β-caryophyllene protects rat liver from carbon tetrachloride-induced fibrosis by inhibiting hepatic stellate cell activation. Brit. J. Nutr. 2013, 109(03):394-401.
21. Cappelletto P., Brizzi M., Mongardini F., et al. Italy-grown hemp: yield, composition and cannabinoid content. Ind. Crops Prod. 2001, 13(2):101-113.
22. Carlini E.A., Cunha J.M. Hypnotic and antiepileptic effects of cannabidiol. J. Clin. Pharmacol. 1981, 21(S1):417S-427S.
23. Chang H.-J., Kim J.-M., Lee J.-C., et al. Protective effect of β-caryophyllene, a natural bicyclic sesquiterpene, against cerebral ischemic injury. J. Med. Food 2013, 16(6):471-480.
24. Chaves J.S., Leal P.C., Pianowisky L., et al. Pharmacokinetics and tissue distribution of the sesquiterpene alpha-humulene in mice. Planta Med. 2008, 74(14):1678-1683.
25. Cheng Y., Dong Z., Liu S. β-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 mice through CB2 receptor activation and the PPARγ pathway. Pharmacology 2014, 94(1-2):1-12.
26. Chopra I.C., Chopra R.N. The use of the cannabis drugs in India. Bull. Narcot. 1957, 9(1):4-29.
27. Ciftci O., Ozdemir I., Tanyildizi S., et al. Antioxidative effects of curcumin, β-myrcene and 1, 8-cineole against 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin-induced oxidative stress in rats liver. Toxicol. Ind. Health 2011, 27(5):447-453.
28. Consroe P., Wolkin A. Cannabidiol - antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J. Pharmacol. Exp. Therap. 1977, 201(1):26-32.
29. Crippa J.A., Zuardi A.W., Martín-Santos R., et al. Cannabis and anxiety: a critical review of the evidence. Hum. Psychopharmacol. Clin. Exp. 2009, 24(7):515-523.
30. Crowell P.L., Gould M.N. Chemoprevention and therapy of cancer by d-Limonene. CRC Crit. Rev. Oncol. 1994, 5(1):1-22.
31. Dayanandan P., Kaufman P.B. Trichomes of Cannabis sativa L. (Cannabaceae). Am. J. Bot. 1976, 63(5):578-591.
32. Deferne J.-L., Pate D.W. Hemp seed oil: a source of valuable essential fatty acids. J. Int. Hemp. Assoc. 1996, 3(1):4-7.
33. Directive C. Common catalogue of varieties of agricultural plant species. Off. J. Eur. Union 2013, 379(1).
34. Dittrich H., Kutchan T.M. Molecular cloning, expression, and induction of berberine bridge enzyme, an enzyme essential to the formation of benzophenanthridine alkaloids in the response of plants to pathogenic attack. Proc. Nat. Acad. Sci. U.S.A. 1991, 88(22):9969-9973.
35. Drugs U.N.O.O. Recommended Methods for the Identification and Analysis of Cannabis and Cannabis Products 2009, United Nations Publications.
36. Dwarakanath C. Use of opium and cannabis in the traditional systems of medicine in India. Bull. Narcot. 1965, 17(1):15-19.
37. ElSohly H.N., Turner C.E., Clark A.M., et al. Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds. J. Pharmaceut. Sci. 1982, 71(12):1319-1323.
38. ElSohly M.A., Ross S.A., Mehmedic Z., et al. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J. Forens. Sci. 2000, 45(1):24-30.
39. ElSohly M.A., Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005, 78(5):539-548.
40. Esposito G., Scuderi C., Savani C., et al. Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. Brit. J. Pharmacol. 2007, 151(8):1272-1279.
41. Fellermeier M., Eisenreich W., Bacher A., et al. Biosynthesis of cannabinoids. Eur. J. Biochem. 2001, 268(6):1596-1604.
42. Fernandes E.S., Passos G.F., Medeiros R., et al. Anti-inflammatory effects of compounds alpha-humulene and (-)-trans-caryophyllene isolated from the essential oil of Cordia verbenacea. Eur. J. Pharmacol. 2007, 569(3):228-236.
43. Fischedick J.T., Hazekamp A., Erkelens T., et al. Metabolic fingerprinting of Cannabis sativa L., cannabinoids and terpenoids for chemotaxonomic and drug standardization purposes. Phytochemistry 2010, 71(17-18):2058-2073.
44. Gagne S.J., Stout J.M., Liu E., et al. Identification of olivetolic acid cyclase from Cannabis sativa reveals a unique catalytic route to plant polyketides. Proc. Nat. Acad. Sci. U.S.A. 2012, 109(31):12811-12816.
45. Gerritsen M.E., Carley W.W., Ranges G.E., et al. Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression. Am. J. Pathol. 1995, 147(2):278-292.
46. Gertsch J. Anti-inflammatory cannabinoids in diet - towards a better understanding of CB2 receptor action? Towards a better understanding of CB2 receptor action?. Commun. Integr. Biol. 2008, 1(1):26-28.
47. Gertsch J., Leonti M., Raduner S., et al. Beta-caryophyllene is a dietary cannabinoid. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(26):9099-9104.
48. Gertsch J., Pertwee R.G., Di Marzo V. Phytocannabinoids beyond the Cannabis plant-do they exist?. Brit. J. Pharmacol. 2010, 160(3):523-529.
49. Gómez M.T.S., García M.D., Fernández M.A. Study of the topical anti-inflammatory activity of Achillea ageratum on chronic and acute inflammation models. Zeitschrift für Naturforschung C 1999, 54c(11):937-941.
50. Gurgel do Vale T., Couto Furtado E., Santos J.G., et al. Central effects of citral, myrcene and limonene, constituents of essential oil chemotypes from Lippia alba (Mill.) N.E. Brown. Phytomedicine 2002, 9(8):709-714.
51. Hampson A., Grimaldi M., Axelrod J., et al. Cannabidiol and (-)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U.S.A. 1998, 95(14):8268-8273.
52. Hayakawa K., Mishima K., Irie K., et al. Cannabidiol prevents a post-ischemic injury progressively induced by cerebral ischemia via a high-mobility group box1-inhibiting mechanism. Neuropharmacology 2008, 55(8):1280-1286.
53. Hellerman, C., 2013. Is Super Weed, Super Bad? CNN News. Available from:. http://www.cnn.com/2013/08/09/health/weed-potency-levels/.
54. Hill A.J., Williams C.M., Whalley B.J., et al. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol. Therap. 2012, 133(1):79-97.
55. Hillig K.W. A chemotaxonomic analysis of terpenoid variation in Cannabis. Biochem. Systemat. Ecol. 2004, 32(10):875-891.
56. Hillig K.W., Mahlberg P.G. A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). Am. J. Bot. 2004, 91(6):966-975.
57. Hirota R., Roger N.N., Nakamura H., et al. Anti-inflammatory effects of limonene from Yuzu (citrus junos tanaka) essential oil on eosinophils. J. Food Sci. 2010, 75(3):H87-H92.
58. Hirota R., Nakamura H., Bhatti S.A., et al. Limonene inhalation reduces allergic airway inflammation in Dermatophagoides farinae-treated mice. Inhal. Toxicol. 2012, 24(6):373-381.
59. Izzo A.A., Borrelli F., Capasso R., et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci. 2009, 30(10):515-527.
60. Kalra E. Nutraceutical-definition and introduction. AAPS Pharm. Sci. 2003, 5(3):27-28.
61. Kapoor R., Huang Y.-S. Gamma linolenic acid: an anti-inflammatory omega-6 fatty acid. Curr. Pharmaceut. Biotechnol. 2006, 7(6):531-534.
62. Komiya M., Takeuchi T., Harada E. Lemon oil vapor causes an anti-stress effect via modulating the 5-HT and DA activities in mice. Behav. Brain Res. 2006, 172(2):240-249.
63. Lamarck, J.-B., 1811. Encyclopédie méthodique, botanique: Suppl. 2: Panckoucke.
64. Le Foll B., Trigo J.M., Sharkey K.A., et al. Cannabis and Δ9-tetrahydrocannabinol (THC) for weight loss?. Med. Hypoth. 2013, 80(5):564-567.
65. Legault J., Pichette A. Potentiating effect of β-caryophyllene on anticancer activity of α-humulene, isocaryophyllene and paclitaxel. J. Pharm. Pharmacol. 2007, 59(12):1643-1647.
66. Leizer C., Ribnicky D., Poulev, et al. The composition of hemp seed oil and its potential as an important source of nutrition. J. Nutraceut. Funct. Med. Foods 2000, 2(4):35-54.
67. Li H.-L. An archaeological and historical account of cannabis in China. Econ. Bot. 1973, 28(4):437-448.
68. Ligresti A., Moriello A.S., Starowicz K., et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exper. Therap. 2006, 318(3):1375-1387.
69. Lima N.G.P.B., De Sousa D.P., Pimenta F.C.F., et al. Anxiolytic-like activity and GC-MS analysis of (R)-(+)-limonene fragrance, a natural compound found in foods and plants. Pharmacol. Biochem. Behav. 2013, 103(3):450-454.
70. Linnaeus C. Species Plantarum 1800, vol. 4. Impensis GC Nauk.
71. Lorenzetti B.B., Souza G.E.P., Sarti S.J., et al. Myrcene mimics the peripheral analgesic activity of lemongrass tea. J. Ethnopharmacol. 1991, 34(1):43-48.
72. Mahmoud M.F., El Swefy S., Hasan R.A., et al. Role of cannabinoid receptors in hepatic fibrosis and apoptosis associated with bile duct ligation in rats. Eur. J. Pharmacol. 2014, 742:118-124.
73. Makriyannis A. 2012 Division of medicinal chemistry award address. Tracking the cannabinoid road: a personal perspective. J. Med. Chem. 2014, 57(10):3891-3911.
74. Marks M.D., Tian L., Wenger J.P., et al. Identification of candidate genes affecting Δ9-tetrahydrocannabinol biosynthesis in Cannabis sativa. J. Exper. Bot. 2009, erp210.
75. McPartland J.M., Russo E.B. Cannabis and cannabis extracts: greater than the sum of their parts?. J. Cannabis Therap. 2001, 1(3-4):103-132.
76. McPartland J.M., Duncan M., Di Marzo V., et al. Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Brit. J. Pharmacol. 2015, 172(3):737-753.
77. Mechanics P. New billion-dollar crop. Popular Mechanics 1938, pp. 238-238.
78. Mediavilla V., Steinemann S. Essential oil of Cannabis sativa L. strains. J. Int. Hemp. Assoc. 1997, 4:80-82.
79. Mehmedic Z., Chandra S., Slade D., et al. Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J. Forens. Sci. 2010, 55(5):1209-1217.
80. Morimoto S., Komatsu K., Taura F., et al. Enzymological evidence for cannabichromenic acid biosynthesis. J. Nat. Prod. 1997, 60(8):854-857.
81. Novak J., Zitterl-Eglseer K., Deans S.G., et al. Essential oils of different cultivars of Cannabis sativa L. and their antimicrobial activity. Flav. Fragr. J. 2001, 16(4):259-262.
82. Pant A., Saikia S.K., Shukla V., et al. Beta-caryophyllene modulates expression of stress response genes and mediates longevity in Caenorhabditis elegans. Exp. Gerontol. 2014, 57:81-95.
83. Pertwee R.G. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Exp. Opin. Investig. Drugs 2000, 9(7):1553-1571.
84. Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Brit. J. Pharmacol. 2008, 153(2):199-215.
85. Pertwee R.G., Thomas A., Stevenson L.A., et al. The psychoactive plant cannabinoid, Δ9-tetrahydrocannabinol, is antagonized by Δ8- and Δ9-tetrahydrocannabivarin in mice in vivo. Brit. J. Pharmacol. 2007, 150(5):586-594.
86. Radwan M.M., ElSohly M.A., Slade D., et al. Non-cannabinoid constituents from a high potency Cannabis sativa variety. Phytochemistry 2008, 69(14):2627-2633.
87. Rao V.S.N., Menezes A.M.S., Viana G.S.B. Effect of myrcene on nociception in mice. J. Pharm. Pharmacol. 1990, 42(12):877-878.
88. Riedel G., Fadda P., McKillop-Smith S., et al. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Brit. J. Pharmacol. 2009, 156(7):1154-1166.
89. Rock E.M., Parker L.A. Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats. Brit. J. Pharmacol. 2013, 169(3):685-692.
90. Rock E.M., Limebeer C.L., Navaratnam R., et al. A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping. Psychopharmacology 2014, 231(16):3207-3215.
91. Rogerio A.P., Andrade E.L., Leite D.F., et al. Preventive and therapeutic anti-inflammatory properties of the sesquiterpene α-humulene in experimental airways allergic inflammation. Brit. J. Pharmacol. 2009, 158(4):1074-1087.
92. Ross S.A., ElSohly M.A. The volatile oil composition of fresh and air-dried buds of Cannabis sativa. J. Nat. Prod. 1996, 59(1):49-51.
93. Rufino A.T., Ribeiro M., Sousa C., et al. Evaluation of the anti-inflammatory, anti-catabolic and pro-anabolic effects of E-caryophyllene, myrcene and limonene in a cell model of osteoarthritis. Eur. J. Pharmacol. 2015, 750(0):141-150.
94. Russo E.B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Brit. J. Pharmacol. 2011, 163(7):1344-1364.
95. Rustichelli C., Ferioli V., Baraldi M., et al. Analysis of cannabinoids in fiber hemp plant varieties (Cannabis sativa L.) by high-performance liquid chromatography. Chromatographia 1998, 48(3-4):215-222.
96. Salgueiro J.B., Ardenghi P., Dias M., et al. Anxiolytic natural and synthetic flavonoid ligands of the central benzodiazepine receptor have no effect on memory tasks in rats. Pharmacol. Biochem. Behav. 1997, 58(4):887-891.
97. Satsu H., Matsuda T., Toshimitsu T., et al. Regulation of interleukin-8 secretion in human intestinal epithelial Caco-2 cells by α-humulene. Biofactors 2004, 21(1-4):137-139.
98. Sauer M.A., Rifka S.M., Hawks R.L., et al. Marijuana: interaction with the estrogen receptor. J. Pharmacol. Exper. Therap. 1983, 224(2):404-407.
99. Schmitt S., Schaefer U.F., Doebler L., et al. Cooperative interaction of monoterpenes and phenylpropanoids on the in vitro human skin permeation of complex composed essential oils. Planta Med. 2009, 75(13):1381-1385.
100. Schultes R.E., Klein W.M., Plowman T., et al. Cannabis: An Example of Taxonomic Neglect. Botanical Museum Leaflets 1974, Harvard University, pp. 337-367.
101. Schultz O.E., Haffner G.A. A sedative and antibacterial principle in German hemp (Cannabis sativa). Naturforsch 1958, 14b:98-100.
102. Sell C. Handbook of Essential Oils: Science, Technology, and Applications 2009, CRC Press, New York, NY.
103. Shoyama Y., Hirano H., Nishioka I. Biosynthesis of propyl cannabinoid acid and its biosynthetic relationship with pentyl and methyl cannabinoid acids. Phytochemistry 1984, 23(9):1909-1912.
104. Shoyama Y., Takeuchi A., Taura F., et al. Crystallization of 1-tetrahydrocannabinolic acid (THCA) synthase from Cannabis sativa. Acta Crystallographica Sect. F: Struct. Biol. Crystall. Commun. 2005, 61(8):799-801.
105. Shoyama Y., Yagi M., Nishioka I., et al. Biosynthesis of cannabinoid acids. Phytochemistry 1975, 14(10):2189-2192.
106. Si D., Wang Y., Zhou Y.-H., Guo Y., et al. Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug Metab. Dispos. 2009, 37(3):629-634.
107. Silvestri C., Paris D., Martella A., et al. Two non-psychoactive cannabinoids reduce intra-cellular lipid levels and inhibit hepatosteatosis. J. Hepatol. 2015.
108. Simopoulos A.P. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed. Pharmacother. 2002, 56(8):365-379.
109. Sirikantaramas S., Morimoto S., Shoyama Y., et al. The gene controlling marijuana psychoactivity. Molecular cloning andheterologous expression of Δ1-tetrahydrocannabinolic acid synthase from Cannabis sativa L. J. Biol. Chem. 2004, 279(38):39767-39774.
110. Sirikantaramas S., Taura F., Morimoto S., et al. Recent advances in Cannabis sativa research: biosynthetic studies and its potential in biotechnology. Curr. Pharmaceut. Biotechnol. 2007, 8(4):237-243.
111. Sirikantaramas S., Taura F., Tanaka Y., et al. Tetrahydrocannabinolic acid synthase, the enzyme controlling marijuana psychoactivity, is secreted into the storage cavity of the glandular trichomes. Plant Cell Physiol. 2005, 46(9):1578-1582.
112. Small E. American law and the species problem in Cannabis: science and semantics. Bull. Narcot. 1975, 27(3):1-20.
113. Small E., Marcus D. Hemp: a new crop with new uses for North America. Trends New Crops New Uses 2002, 284-326.
114. Small E., Marcus D. Tetrahydrocannabinol levels in hemp (Cannabis sativa) germplasm resources. Econ. Bot. 2003, 57(4):545-558.
115. Takeda S., Misawa K., Yamamoto I., et al. Cannabidiolic acid as a selective cyclooxygenase-2 inhibitory component in cannabis. Drug Metab. Dispos. 2008, 36(9):1917-1921.
116. Tate G., Mandell B., Laposata M., et al. Suppression of acute and chronic inflammation by dietary gamma linolenic acid. J. Rheumatol. 1989, 16(6):729-734.
117. Taura F., Morimoto S., Shoyama Y. Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L. Biochemical analysis of a novel enzyme that catalyzes the oxidocyclization of cannabigerolic acid to cannabidiolic acid. J. Biol. Chem. 1996, 271(29):17411-17416.
118. Taura F., Sirikantaramas S., Shoyama Y., et al. Phytocannabinoids in Cannabis sativa: recent studies on biosynthetic enzymes. Chem. Biodiver 2007, 4(8):1649-1663.
119. Thomas Prates Ong M.T.C., de Conti A., Moreno F.S. Chemoprevention of hepatocarcinogenesis with dietary isoprenic derivatives: cellular and molecular aspects. Curr. Cancer Drug Targets 2012, 12(9):1173-1190.
120. Touw M. The religious and medicinal uses of Cannabis in China, India and Tibet. J. Psychoact. Drugs 1981, 13(1):23-34.
121. Trembly, B., Sherman, M., 1990. Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Paper presented at the Marijuana'90 International Conference on Cannabis and Cannabinoids. Kolympari, Crete, July 8.
122. Turner C.E., Elsohly M.A. Biological activity of cannabichromene, its homologs and isomers. J. Clin. Pharmacol. 1981, 21(S1):283S-291S.
123. Turner C.E., Elsohly M.A., Boeren E.G. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J. Nat. Prod. 1980, 43(2):169-234.
124. Ulbricht C. Focus: diabetes. J. Dietary Suppl. 2011, 8(3):239-256.
125. Upton, R., Craker, L., ElSohly, M., et al., 2014. Cannabis Inflorescence: Standards of Identity, Analysis, and Quality Control. Scott's Valley, CA.
126. van Bakel H., Stout J.M., Cote A.G., et al. The draft genome and transcriptome of Cannabis sativa. Genome Biol. 2011, 12(10):R102.
127. Vemuri V.K., Makriyannis A. The medicinal chemistry of cannabinoids. Clin. Pharmacol. Therap. 2015, 97(6):553-558.
128. Veress T., Szanto J., Leisztner L. Determination of cannabinoid acids by high-performance liquid chromatography of their neutral derivatives formed by thermal decarboxylation: I. Study of the decarboxylation process in open reactors. J. Chromatogr. A 1990, 520:339-347.
129. Virovets V. Selection for non-psychoactive hemp varieties (Cannabis sativa L.) in the CIS (former USSR). J. Intl. Hemp. Assoc. 1996, 3:13-15.
130. Vogelmann A.F., Turner J.C., Mahlberg P.G. Cannabinoid composition in seedlings compared to adult plants of Cannabis sativa. J. Nat. Prod. 1988, 51(6):1075-1079.
131. Wagner G.J. Secreting glandular trichomes: more than just hairs. Plant Physiol. 1991, 96(3):675-679.
132. Wargent E., Zaibi M., Silvestri C., et al. The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutr. Diabetes 2013, 3(5):e68.
133. Watson D.P., Clarke R.C. The genetic future of hemp. Int. Hemp. Assoc. 2014, Available from: http://www.hempworld.com/hemp-cyberfarm_com/htms/research_orgzs/iha/ihagenetic.html.
134. Wilt T.J., Macdonald R., Ishani A. β-sitosterol for the treatment of benign prostatic hyperplasia. A systamic review. BJU Int. 1999, 83(9):976-983.
135. Woelkart K., Xu W., Pei Y., et al. The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots. Planta Med. 2005, 71(08):701-705.
136. Wood W.F., Sollers B.G., Dragoo G.A., et al. Volatile components in defensive spray of the hooded skunk, Mephitis macroura. J. Chem. Ecol. 2002, 28(9):1865-1870.
137. Xi Z.-X., Peng X.-Q., Li X., et al. Brain cannabinoid CB2 receptors modulate cocaine's actions in mice. Nat. Neurosci. 2011, 14(9):1160-1166.
138. Zuardi A., Karniol I. Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination. Brazil. J. Med. Biol. Res. 1983, 16(2):141-146.
139. Zuardi A., Guimaraes F., Moreira A. Effect of cannabidiol on plasma prolactin, growth hormone and cortisol in human volunteers. Brazil J. Med. Biol. Res. 1993, 26(2):213-217.